Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as DVS SR
DVS · 4 trials · 2 indications
A TEAE was defined as an event that was absent before treatment and emerged or worsened during the treatment period.
A TEAE was defined as an event that was absent before treatment and emerged or worsened during the treatment period.
HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Items are scored on either a 3 point (0 to 2) or a 5 point scale (0 to 4), with 0=none/absent and 4=most severe, for a maximum total score of 50.
| Arm | Type | Description |
|---|---|---|
| Desvenlafaxine Succinate Sustained-Release | EXPERIMENTAL | - |
| A | EXPERIMENTAL | DVS SR 50mg/day |
| B | EXPERIMENTAL | DVS SR 100mg/day |
| C | EXPERIMENTAL | DVS SR 200mg/day |
| D | ACTIVE_COMPARATOR | Paroxetine 20mg/day |
| Name | Type | Description |
|---|---|---|
| DVS SR | DRUG | Subjects will receive a flexible-dose of 20, 25, 35, or 50 mg/day as prescribed by the investigator |
| Paroxetine | DRUG | 20 mg Paroxetine capsule, QD, 8 weeks treatment with 2 week taper |
| DVS-SR 50 mg | DRUG | - |
| DVS-SR 100 mg | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: * Completed study B2061032 and who in the investigator's opinion, would benefit from long term treatment with DVS SR * Willingness and ability to comply with scheduled visits, treatment plan, and procedures Exclusion Criteria: * Requires precaution against suicide * Not in gen...
Top 20 of 31 competitors
DVS is used for the treatment of major depressive disorder. It has been studied in both adult and pediatric outpatients, including children and adolescents aged 7 years and older. The clinical program includes four completed Phase 3 trials with a total enrollment of 1,839 participants.
DVS is developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer sponsored the Phase 3 clinical program evaluating DVS in major depressive disorder, including adult and pediatric studies conducted across multiple countries.
DVS is in Phase 3 clinical development for major depressive disorder. Four Phase 3 trials have been completed, and no active trials are currently listed. The completed studies enrolled a total of 1,839 participants and included randomized, double-blind, active-controlled designs.
DVS has been evaluated in four completed Phase 3 trials: NCT01371721, NCT01371708, NCT00445679, and NCT00277823. These studies covered adult and pediatric outpatients with major depressive disorder and were conducted in countries including the United States, Mexico, Chile, China, India, South Korea, and Taiwan.
Yes, DVS is also known as DVS SR and DVS-SR 50 mg. DVS SR refers to the sustained-release formulation of desvenlafaxine, which was studied in the Phase 3 clinical program for major depressive disorder. These names refer to the same investigational drug asset.